Funder
Suomen Kulttuurirahasto
Suomen Lääketieteen Säätiö
Subject
Neurology (clinical),Neurology,General Medicine
Reference67 articles.
1. The importance of measuring cotinine levels to identify smokers in clinical trials;Apseloff;Clin. Pharmacol. Ther.,1994
2. Fatigue in multiple sclerosis - Insights into evaluation and management;Ayache;Neurophysiol. Clin. Clin. Neurophysiol.,2017
3. Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia;Bónitto;Mult. Scler. Relat. Disord.,2022
4. Depression and anxiety amongst multiple sclerosis patients;Beiske;Eur. J. Neurol.,2008
5. Benedict, R, Seze, JD, Hauser, S, Kappos, L, Wolinsky, J, Zheng, H, et al., 2018. Impact of ocrelizumab on cognition in patients at increased risk of progressive disease (P1.420). AAN: https://n.neurology.org/content/90/15_Supplement/P1.420 Poster P1.420 Accessed 4 Oct 2022.